22
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS

      guideline

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Thyroid ultrasound (US) is a key examination for the management of thyroid nodules. Thyroid US is easily accessible, noninvasive, and cost-effective, and is a mandatory step in the workup of thyroid nodules. The main disadvantage of the method is that it is operator dependent. Thyroid US assessment of the risk of malignancy is crucial in patients with nodules, in order to select those who should have a fine needle aspiration (FNA) biopsy performed. Due to the pivotal role of thyroid US in the management of patients with nodules, the European Thyroid Association convened a panel of international experts to set up European guidelines on US risk stratification of thyroid nodules. Based on a review of the literature and on the American Association of Clinical Endocrinologists, American Thyroid Association, and Korean guidelines, the panel created the novel European Thyroid Imaging and Reporting Data System, called EU-TIRADS. This comprises a thyroid US lexicon; a standardized report; definitions of benign and low-, intermediate-, and high-risk nodules, with the estimated risks of malignancy in each category; and indications for FNA. Illustrated by numerous US images, the EU-TIRADS aims to serve physicians in their clinical practice, to enhance the interobserver reproducibility of descriptions, and to simplify communication of the results.

          Related collections

          Author and article information

          Journal
          ETJ
          ETJ
          10.1159/issn.2235-0640
          European Thyroid Journal
          S. Karger AG
          2235-0640
          2235-0802
          2017
          September 2017
          08 August 2017
          : 6
          : 5
          : 225-237
          Affiliations
          [_a] aThyroid and Endocrine Tumors, Institute of Endocrinology, Pitié Salpêtrière Hospital, Pierre and Marie Curie University, Paris, France
          [_b] bDepartment of Endocrinology, Odense University Hospital, Odense, Denmark
          [_c] cDepartment of Endocrinology and Metabolism, University of Ankara School of Medicine, İbni Sina Hastanesi, Ankara, Turkey
          [_d] dDepartment of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy
          [_e] eHead Neck and Thyroid Imaging, Department of Radiology, Guy’s and St Thomas’ Hospitals NHS Foundation Trust, London, United Kingdom
          Author notes
          *Laurence Leenhardt, MD, PhD, Thyroid and Endocrine Tumors Institute of Endocrinology, Pitié Salpêtrière Hospital, Pierre and Marie Curie University, 83 Bd de l’Hôpital, FR–75651 Paris Cedex 13 (France), E-Mail laurence.leenhardt@aphp.fr
          Author information
          https://orcid.org/0000-0001-8036-6050
          Article
          478927 PMC5652895 Eur Thyroid J 2017;6:225–237
          10.1159/000478927
          PMC5652895
          29167761
          4d2c43c6-cebf-4021-a2ef-13ec2bff1a49
          © 2017 European Thyroid Association. Published by S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 04 May 2017
          : 17 June 2017
          Page count
          Figures: 12, Tables: 2, Pages: 13
          Categories
          Guidelines

          Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
          Risk of malignancy,Guidelines,Ultrasound,Fine needle aspiration,TIRADS,Thyroid nodule

          Comments

          Comment on this article